OTTAWA, ONTARIO, February 7, 2013 - Avivagen Inc. (TSXV:VIV), a wellness company, is pleased to report their recent attendance at the 2013 International Production & Processing Expo (IPPE) in Atlanta, Georgia. Avivagen CEO David Hankinson attended the three day conference that is considered the premier event in the industry and includes three integrated trade shows - The International Poultry Expo, The International Feed Expo, and The International Meat Expo - with over 1,150 exhibitors showcasing the latest technologies, trends, and products in the industry.
Attending thought-leading conferences such as IPPE is an important component in Avivagen's strategy to continue to build brand awareness for Oximunol(TM) and other products based on the Company's patented oxidized carotenoid (OxC-beta) technology prior to their launch as food animal feed supplement alternatives to address the large need for new, safe and effective non-antiobiotic growth promotion agents for food producing animals. The growing global awareness of and concern about human health implications of the rise of antibiotic resistant bacteria, potentially linked to the heavy use of antibiotics for disease prevention and growth promotion in food animals, is driving a search for alternatives. Avivagen has identified OxC-beta as a non-antibiotic alternative to promote growth and feed conversion in food animals with supporting evidence previously reported by the Company in both pigs and poultry. Because feed is a major cost factor in the production of food from animals, any improvement in the ability of the animal to convert feed into food products or enhancement in growth rate has the potential to significantly improve the economics for food producers.
CEO David Hankinson commented that "attending industry events like the IPPE and meeting key players is crucial to Avivagen management understanding the needs of producers and building relationships with industry partners and potential customers. It was an excellent opportunity to grow awareness of OxC-beta so that Avivagen's products are accepted as solutions to some of the critical challenges and pressures the food-producing industry now faces. The novelty of OxC-beta is that its immune function benefits to the overall health of animals translate into both cost savings and quality benefits for the consumer and producer alike. These are important considerations in forging alliances with industry partners."
OxC-beta is Avivagen's proprietary, concentrated source of oxidized carotenoids, containing oxidation compounds that occur extensively in the plant world in minute amounts. Avivagen is developing OxC-beta as a non-antibiotic alternative feed additive for promoting health in the global food animal market. Results of clinical trials in animals and in vitro studies indicate OxC-beta helps support immune function, which can result in general overall health improvement. Specific benefits include healthy growth, better utilization of feed and decreased mortality in poultry and swine.
Avivagen, a wellness company, is committed to developing and delivering products to humans and animals to assist in optimizing health and daily quality of life. Avivagen is advancing product candidates for the food animal market, companion animal market and various, potential human applications. More information can be found at www.Avivagen.com.
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Avivagen Inc. and Avivagen Animal Health Inc. and the environment in which their respective businesses operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Avivagen Inc. and Avivagen Animal Health Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. The results of treatment described above are based on historical results. Different animals may experience different results from the treatments described above.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information contact:
|Avivagen Inc. David |Avivagen Inc. Graham |
|Hankinson CEO Tel: |Burton President Tel:|
|902-825-9270 |613-990-0969 |
Leave a comment...